Quarterly report pursuant to Section 13 or 15(d)

Disclosure of Correction of Immaterial Error (Summary of Reclassifications) (Details)

v3.21.1
Disclosure of Correction of Immaterial Error (Summary of Reclassifications) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Operating expense:        
Cost of goods sold $ 493 $ 86 $ 1,275 $ 404
Research and Development 2,162 1,095 6,892 2,990
General and administrative 5,313 2,979 15,385 8,198
Total operating expenses 7,475 4,074 22,277 11,188
Eliminations [Member]        
Operating expense:        
Research and Development (691) (801) (1,210) (1,303)
General and administrative (187) (197) (642) (613)
iBio, Inc. [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold 229 72 425 341
Research and Development 1,500 14 2,341 413
General and administrative 3,438 1,576 8,921 3,796
iBio CDMO [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold 264 14 850 63
Research and Development 1,353 1,882 5,761 3,880
General and administrative $ 2,062 1,600 $ 7,106 5,015
Statement of Operations Reclassifications [Member]        
Operating expense:        
Cost of goods sold   86   404
Research and Development   1,095   2,990
General and administrative   2,979   8,198
Total operating expenses   $ 4,160   $ 11,592
Cost of goods sold, % change   100.00%   100.00%
Research and Development, % change   10.00%   4.00%
General and administrative, % change   (6.00%)   (6.00%)
Statement of Operations Reclassifications [Member] | As Reported [Member]        
Operating expense:        
Research and Development   $ 999   $ 2,864
General and administrative   3,161   8,728
Total operating expenses   4,160   11,592
Statement of Operations Reclassifications [Member] | Adjustment [Member]        
Operating expense:        
Cost of goods sold   86   404
Research and Development   96   126
General and administrative   (182)   (530)
Segment Reporting Reclassifications [Member]        
Operating expense:        
Cost of goods sold   86   404
Research and Development   1,095   3,976
General and administrative   2,979   8,578
Segment Reporting Reclassifications [Member] | Eliminations [Member]        
Operating expense:        
Research and Development   (801)   (1,307)
General and administrative   (197)   (1,073)
Segment Reporting Reclassifications [Member] | iBio, Inc. [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold   72   341
Research and Development   14   2,829
General and administrative   1,576   3,072
Segment Reporting Reclassifications [Member] | iBio CDMO [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold   14   63
Research and Development   1,882   2,454
General and administrative   1,600   6,579
Segment Reporting Reclassifications [Member] | As Reported [Member]        
Operating expense:        
Research and Development   999   3,850
General and administrative   3,161   9,108
Segment Reporting Reclassifications [Member] | As Reported [Member] | Eliminations [Member]        
Operating expense:        
Research and Development   (801)   (1,307)
General and administrative   (197)   (1,073)
Segment Reporting Reclassifications [Member] | As Reported [Member] | iBio, Inc. [Member] | Operating Segments [Member]        
Operating expense:        
Research and Development   78   3,152
General and administrative   1,584   3,090
Segment Reporting Reclassifications [Member] | As Reported [Member] | iBio CDMO [Member] | Operating Segments [Member]        
Operating expense:        
Research and Development   1,722   2,005
General and administrative   $ 1,774   $ 7,091